Bernard Iung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6763115/publications.pdf

Version: 2024-02-01

424 papers 102,852 citations

97 h-index 308 g-index

482 all docs 482 docs citations

482 times ranked 56727 citing authors

#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2,2	5,583
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
4	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,233
5	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2017, 38, 2739-2791.	2.2	5,142
6	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
7	2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal, 2015, 36, 3075-3128.	2.2	3,902
8	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal, 2014, 35, 2873-2926.	2.2	3,549
9	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	2.2	3,465
10	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
11	A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal, 2003, 24, 1231-1243.	2.2	2,808
12	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
13	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
14	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.2	2,305
15	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
16	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2022, 43, 561-632.	2.2	2,169
17	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal, 2006, 28, 230-268.	2.2	1,802
18	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.8	1,753

#	Article	IF	Citations
19	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	2.2	1,694
20	Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice. Journal of the American Society of Echocardiography, 2009, 22, 1-23.	2.8	1,611
21	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	2.2	1,396
22	Guidelines on the management of valvular heart disease (version 2012). European Journal of Cardio-thoracic Surgery, 2012, 42, S1-S44.	1.4	1,313
23	Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. New England Journal of Medicine, 2018, 379, 2297-2306.	27.0	1,276
24	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	2.2	1,253
25	Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients. New England Journal of Medicine, 2012, 366, 1705-1715.	27.0	1,135
26	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	2.2	971
27	Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?. European Heart Journal, 2005, 26, 2714-2720.	2.2	966
28	Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. European Journal of Echocardiography, 2009, 10, 1-25.	2.3	890
29	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021, 42, 17-96.	2.2	830
30	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
31	What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. European Heart Journal, 2007, 28, 1358-1365.	2.2	763
32	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Heart Journal, 2009, 30, 2769-2812.	2.2	735
33	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647
34	Calcific aortic stenosis. Nature Reviews Disease Primers, 2016, 2, 16006.	30.5	568
35	Epidemiology of valvular heart disease in the adult. Nature Reviews Cardiology, 2011, 8, 162-172.	13.7	547
36	Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey. Clinical Infectious Diseases, 2012, 54, 1230-1239.	5.8	546

#	Article	IF	Citations
37	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2017, 52, 616-664.	1.4	510
38	Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National) Tj ETQq0 0 0 rgBT	Overlock	10 Tf 50 702
39	Recommendations for the management of patients after heart valve surgery. European Heart Journal, 2005, 26, 2463-2471.	2.2	488
40	Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. European Heart Journal, 2019, 40, 3222-3232.	2,2	421
41	Multimodal Assessment of the Aortic Annulus Diameter. Journal of the American College of Cardiology, 2010, 55, 186-194.	2.8	414
42	Infective endocarditis in Europe: lessons from the Euro heart survey. Heart, 2005, 91, 571-575.	2.9	367
43	Determinants of Significant Paravalvular Regurgitation After Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2009, 2, 821-827.	2.9	351
44	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2021, 60, 727-800.	1.4	344
45	European Society of Cardiology: cardiovascular disease statistics 2021. European Heart Journal, 2022, 43, 716-799.	2.2	343
46	2014 ESC/ESA Guidelines on non-cardiac surgery. European Journal of Anaesthesiology, 2014, 31, 517-573.	1.7	335
47	Temporal Trends in Infective Endocarditis in the Context of Prophylaxis Guideline Modifications. Journal of the American College of Cardiology, 2012, 59, 1968-1976.	2.8	327
48	Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart, 2011, 97, 721-726.	2.9	320
49	Contemporary Presentation and Management of Valvular Heart Disease. Circulation, 2019, 140, 1156-1169.	1.6	281
50	Temporal Trends in Transcatheter AorticÂValve Replacement in France. Journal of the American College of Cardiology, 2017, 70, 42-55.	2.8	277
51	Epidemiology of Acquired Valvular Heart Disease. Canadian Journal of Cardiology, 2014, 30, 962-970.	1.7	275
52	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	1.7	263
53	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261
54	Results of Transfemoral or Transapical Aortic Valve Implantation Following a Uniform Assessment in High-Risk Patients With Aortic Stenosis. Journal of the American College of Cardiology, 2009, 54, 303-311.	2.8	257

#	Article	IF	Citations
55	Effect of Early Cerebral Magnetic Resonance Imaging on Clinical Decisions in Infective Endocarditis. Annals of Internal Medicine, 2010, 152, 497.	3.9	228
56	Infective Endocarditis After Transcatheter Aortic Valve Implantation. Circulation, 2015, 131, 1566-1574.	1.6	227
57	Late Results of Percutaneous Mitral Commissurotomy in a Series of 1024 Patients. Circulation, 1999, 99, 3272-3278.	1.6	218
58	The modern epidemiology of heart valve disease. Heart, 2016, 102, 75-85.	2.9	214
59	Recommendations on the management of the asymptomatic patient with valvular heart disease. European Heart Journal, 2002, 23, 1253-1266.	2.2	207
60	MRI of Acute Myocarditis. Chest, 2002, 122, 1638-1648.	0.8	207
61	Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement Procedures. Circulation, 2014, 129, 1415-1427.	1.6	203
62	Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. European Heart Journal, 2005, 26, 1333-1341.	2.2	188
63	Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart, 2014, 100, 1016-1023.	2.9	188
64	Respective Performance of ¹⁸ F-FDG PET and Radiolabeled Leukocyte Scintigraphy for the Diagnosis of Prosthetic Valve Endocarditis. Journal of Nuclear Medicine, 2014, 55, 1980-1985.	5.0	187
65	AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart Valves. Circulation, 1996, 94, 2107-2112.	1.6	184
66	Immediate Results of Percutaneous Mitral Commissurotomy. Circulation, 1996, 94, 2124-2130.	1.6	178
67	Perivalvular abscesses associated with endocarditis Clinical features and prognostic factors of overall survival in a series of 233 cases. European Heart Journal, 1999, 20, 232-241.	2.2	177
68	Valvular Heart Disease in the Community: A European Experience. Current Problems in Cardiology, 2007, 32, 609-661.	2.4	173
69	TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. European Heart Journal, 2016, 37, 2217-2225.	2.2	171
70	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. EuroIntervention, 2013, 8, 1362-1371.	3.2	168
71	The impact of valve surgery on short- and long-term mortality in left-sided infective endocarditis: do differences in methodological approaches explain previous conflicting results?. European Heart Journal, 2011, 32, 2003-2015.	2.2	155
72	ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. European Heart Journal, 2012, 33, 822-828.	2.2	152

#	Article	IF	CITATIONS
73	ESC Working Group on Valvular Heart Disease Position Paper-heart valve clinics: organization, structure, and experiences. European Heart Journal, 2013, 34, 1597-1606.	2.2	150
74	Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. European Journal of Heart Failure, 2019, 21, 1619-1627.	7.1	149
75	Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. European Heart Journal, 2020, 41, 4304-4317.	2.2	147
76	2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. Revista Espanola De Cardiologia (English Ed), 2018, 71, 110.	0.6	131
77	Is a planned caesarean section in women with cardiac disease beneficial?. Heart, 2015, 101, 530-536.	2.9	130
78	Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease. Circulation, 2018, 137, 806-816.	1.6	130
79	Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial. Circulation, 2022, 145, 648-658.	1.6	130
80	Feasibility and Outcomes of Transcatheter Aortic Valve Implantation in High-Risk Patients With Stenotic Bicuspid Aortic Valves. American Journal of Cardiology, 2012, 110, 877-883.	1.6	129
81	Management of tricuspid valve regurgitation. European Journal of Cardio-thoracic Surgery, 2017, 52, 1022-1030.	1.4	129
82	Contemporary results of mitral valve repair for infective endocarditis. Journal of the American College of Cardiology, 2004, 43, 386-392.	2.8	124
83	Clinical Outcomes and Safety of Transfemoral Aortic Valve Implantation Under General Versus Local Anesthesia. Circulation: Cardiovascular Interventions, 2014, 7, 602-610.	3.9	121
84	Vascular complications of transfemoral aortic valve implantation with the Edwards SAPIENâ,,¢ prosthesis: incidence and impact on outcome. EuroIntervention, 2010, 5, 666-672.	3.2	120
85	TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. European Heart Journal, 2022, 43, 654-662.	2.2	119
86	Contemporary surgical or percutaneous management of severe aortic stenosis in the elderly. European Heart Journal, 2008, 29, 1410-1417.	2.2	118
87	Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement. Circulation, 2020, 141, 243-259.	1.6	118
88	Assessment of the Mitral Valve Area in Patients With Mitral Stenosis by Multislice Computed Tomography. Journal of the American College of Cardiology, 2006, 48, 411-413.	2.8	112
89	Brain MRI Findings in Neurologically Asymptomatic Patients with Infective Endocarditis. American Journal of Neuroradiology, 2013, 34, 1579-1584.	2.4	112
90	Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients. Journal of the American College of Cardiology, 2016, 68, 1637-1647.	2.8	109

#	Article	IF	CITATIONS
91	Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. Circulation, 2018, 138, 2597-2607.	1.6	109
92	Functional results 5 years after successful percutaneous mitral commissurotomy in a series of 528 patients and analysis of predictive factors. Journal of the American College of Cardiology, 1996, 27, 407-414.	2.8	108
93	Prognostic Implications of Pulmonary Hypertension in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2014, 7, 240-247.	3.9	107
94	Baseline Characteristics and Prognostic Implications of Pre-Existing and New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2015, 8, 1346-1355.	2.9	103
95	Brief Report: Prevalence of Antineutrophil Cytoplasmic Antibodies in Infective Endocarditis. Arthritis and Rheumatology, 2014, 66, 1672-1677.	5.6	99
96	Cerebral Microbleeds Are Frequent in Infective Endocarditis. Stroke, 2009, 40, 3461-3465.	2.0	97
97	Late Results of Percutaneous Mitral Commissurotomy up to 20 Years. Circulation, 2012, 125, 2119-2127.	1.6	97
98	Diagnosis of left atrial thrombi in mitral stenosis-usefulness of ultrasound techniques compared with other methods. European Heart Journal, 1991, 12, 70-76.	2.2	95
99	Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes. EuroIntervention, 2011, 7, 549-555.	3.2	94
100	Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: Association with postoperative cardiac dysfunction and 1-year mortality*. Critical Care Medicine, 2006, 34, 995-1000.	0.9	92
101	Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. European Heart Journal Cardiovascular Imaging, 2013, 14, 586-594.	1.2	85
102	Transseptal Transcatheter Mitral Valve Replacement Using Balloon-Expandable Transcatheter Heart Valves. JACC: Cardiovascular Interventions, 2017, 10, 1905-1919.	2.9	85
103	Long-Term Mortality and EarlyÂValveÂDysfunction AccordingÂtoÂAnticoagulation Use. Journal of the American College of Cardiology, 2019, 73, 13-21.	2.8	85
104	Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience. European Heart Journal, 2018, 39, 2679-2689.	2.2	84
105	Standards defining a â€~Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Heart Journal, 2017, 38, 2177-2183.	2.2	83
106	Usefulness of percutaneous balloon commissurotomy for mitral stenosis during pregnancy. American Journal of Cardiology, 1994, 73, 398-400.	1.6	82
107	The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. Journal of Infection, 2016, 72, 544-553.	3.3	82
108	Degenerative calcific aortic stenosis: a natural history. Heart, 2012, 98, iv7-iv13.	2.9	80

#	Article	IF	CITATIONS
109	Three-dimensional evaluation of the mitral valve area and commissural opening before and after percutaneous mitral commissurotomy in patients with mitral stenosis. European Heart Journal, 2006, 28, 72-79.	2.2	75
110	Surgical and interventional management of mitral valve regurgitation: a position statement from the European Society of Cardiology Working Groups on Cardiovascular Surgery and Valvular Heart Disease. European Heart Journal, 2016, 37, 133-139.	2.2	75
111	Characterization of ¹⁸ F-Fluorodeoxyglucose Uptake Pattern in Noninfected Prosthetic Heart Valves. Circulation: Cardiovascular Imaging, 2017, 10, e005585.	2.6	75
112	Femoral Versus Nonfemoral PeripheralÂAccess for TranscatheterÂAortic ValveÂReplacement. Journal of the American College of Cardiology, 2019, 74, 2728-2739.	2.8	75
113	Comprehensive evaluation of preoperative patients with aortic valve stenosis: usefulness of cardiac multidetector computed tomography. Heart, 2007, 93, 1121-1125.	2.9	74
114	Determinants of Cerebral Lesions in Endocarditis on Systematic Cerebral Magnetic Resonance Imaging. Stroke, 2013, 44, 3056-3062.	2.0	74
115	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Kardiologia Polska, 2019, 77, 245-326.	0.6	74
116	Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. American Journal of Cardiology, 1999, 84, 515-518.	1.6	73
117	Temporal trends in percutaneous mitral commissurotomy over a 15-year period. European Heart Journal, 2004, 25, 701-707.	2.2	73
118	Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention, 2015, 10, e1-e9.	3.2	73
119	Infective Endocarditis with Symptomatic Cerebral Complications: Contribution of Cerebral Magnetic Resonance Imaging. Cerebrovascular Diseases, 2013, 35, 327-336.	1.7	72
120	Implementation of Transcatheter Aortic Valve Replacement in France. Journal of the American College of Cardiology, 2018, 71, 1614-1627.	2.8	68
121	Effect of Body Mass Index on 30- and 365-Day Complication andÂSurvival Rates of Transcatheter Aortic Valve Implantation (from the FRench Aortic National CoreValve and Edwards 2 [FRANCE 2] Registry). American Journal of Cardiology, 2013, 112, 1932-1937.	1.6	66
122	Value of multiplane transesophageal echocardiography in determining aortic valve area in aortic stenosis. American Journal of Cardiology, 1996, 77, 882-885.	1.6	65
123	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. International Journal of Cardiology, 2014, 177, 448-454.	1.7	65
124	The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. European Heart Journal, 2014, 35, 2942-2949.	2.2	65
125	Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices. European Heart Journal, 2016, 37, 840-848.	2.2	64
126	The new ESC/EACTS Guidelines on the management of valvular heart disease. Archives of Cardiovascular Diseases, 2012, 105, 465-467.	1.6	63

#	Article	IF	CITATIONS
127	Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Archives of Cardiovascular Diseases, 2013, 106, 209-219.	1.6	63
128	Mitral Regurgitation in Patients Referred for Transcatheter Aortic Valve Implantation Using the Edwards Sapien Prosthesis: Mechanisms and Early Postprocedural Changes. Journal of the American Society of Echocardiography, 2012, 25, 160-165.	2.8	62
129	Transcatheter Valve Replacement in Patients With Severe Mitral Valve Disease and Annular Calcification. Journal of the American College of Cardiology, 2014, 64, 2557-2558.	2.8	60
130	Reappraisal of percutaneous aortic balloon valvuloplasty as a preliminary treatment strategy in the transcatheter aortic valve implantation era. EuroIntervention, 2011, 7, 49-56.	3.2	60
131	Agreement between the new EuroSCORE II, the Logistic EuroSCORE and the Society of Thoracic Surgeons score: Implications for transcatheter aortic valve implantation. Archives of Cardiovascular Diseases, 2014, 107, 353-360.	1.6	59
132	Cerebrovascular Events Post-Transcatheter Aortic Valve Replacement in a Large Cohort of Patients. JACC: Cardiovascular Interventions, 2014, 7, 1138-1145.	2.9	58
133	Management of ischaemic mitral regurgitation. British Heart Journal, 2003, 89, 459-464.	2.1	57
134	Multiple and Mixed Valvular Heart Diseases. Circulation: Cardiovascular Imaging, 2018, 11, e007862.	2.6	57
135	Early assessment by transesophageal echocardiography of left atrial appendage function after percutaneous mitral commissurotomy. American Journal of Cardiology, 1996, 77, 72-76.	1.6	56
136	Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial. American Heart Journal, 2016, 174, 147-153.	2.7	55
137	Immediate and mid-term results of repeat percutaneous mitral commissurotomy for restenosis following earlier percutaneous mitral commissurotomy. European Heart Journal, 2000, 21, 1683-1689.	2.2	53
138	Management of the elderly patient with aortic stenosis. Heart, 2007, 94, 519-524.	2.9	53
139	Relationship between Longitudinal Strain and Symptomatic Status in Aortic Stenosis. Journal of the American Society of Echocardiography, 2013, 26, 868-874.	2.8	53
140	The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. European Heart Journal Quality of Care & Dinical Outcomes, 2019, 5, 202-207.	4.0	53
141	Size-Adjusted Left Ventricular Outflow Tract Diameter Reference Values: A Safeguard for the Evaluation of the Severity of Aortic Stenosis. Journal of the American Society of Echocardiography, 2009, 22, 445-451.	2.8	52
142	Diagnostic Impact of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and White Blood Cell SPECT/Computed Tomography in Patients With Suspected Cardiac Implantable Electronic Device Chronic Infection. Circulation: Cardiovascular Imaging, 2019, 12, e007188.	2.6	52
143	The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention, 2015, 10, 1354-1360.	3.2	52
144	Early Hemodynamic Changes Versus Peak Values: What Is More Useful to Predict Occurrence of Dyspnea During Stress Echocardiography in Patients with Asymptomatic Mitral Stenosis?. Journal of the American Society of Echocardiography, 2011, 24, 392-398.	2.8	51

#	Article	IF	Citations
145	Current Indications for Transcatheter Mitral Valve Replacement Using Transcatheter Aortic Valves. Circulation, 2021, 143, 178-196.	1.6	50
146	VALVE DISEASE: Interface between valve disease and ischaemic heart disease. British Heart Journal, 2000, 84, 347-352.	2.1	49
147	Transcatheter Aortic Valve Implantation: Selection Strategy Is Crucial for Outcome. Annals of Thoracic Surgery, 2009, 87, 1757-1763.	1.3	49
148	Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. European Heart Journal Cardiovascular Imaging, 2012, 13, 703-710.	1.2	49
149	Clinical Results of Transcatheter Aortic Valve Implantation in Octogenarians and Nonagenarians: Insights From the FRANCE-2 Registry. Annals of Thoracic Surgery, 2014, 97, 29-36.	1.3	49
150	Staphylococcus aureus infective endocarditis versus bacteremia strains: Subtle genetic differences at stake. Infection, Genetics and Evolution, 2015, 36, 524-530.	2.3	49
151	Transcatheter heart valve interventions: where are we? Where are we going?. European Heart Journal, 2019, 40, 422-440.	2.2	49
152	Does rheumatic myocarditis really exists? Systematic study with echocardiography and cardiac troponin I blood levels. European Heart Journal, 2003, 24, 855-862.	2.2	48
153	Simple Scoring System to Predict Inâ€Hospital Mortality After Surgery for Infective Endocarditis. Journal of the American Heart Association, 2017, 6, .	3.7	47
154	Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia. Clinical Microbiology and Infection, 2019, 25, 481-488.	6.0	47
155	Long-term outcome after transcatheter aortic valve implantation. Heart, 2015, 101, 936-942.	2.9	46
156	Assessment of Long-Term Structural Deterioration of Transcatheter Aortic Bioprosthetic Valves Using the New European Definition. Circulation: Cardiovascular Interventions, 2019, 12, e007597.	3.9	46
157	Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. European Heart Journal, 2018, 39, 1295-1303.	2.2	43
158	Impact of Direct Transcatheter AorticÂValve Replacement Without BalloonÂAorticÂValvuloplasty on ProceduralÂandÂClinicalÂOutcomes. JACC: Cardiovascular Interventions, 2018, 11, 1956-1965.	2.9	42
159	Impact of prea€•and posta€procedural anemia on the incidence of acute kidney injury and 1a€year mortality in patients undergoing transcatheter aortic valve implantation (from the <scp>F</scp> rench) Tj ETQq1 1 0.784314	rgBT /Ove	erlock 10 Tf 41
160	Management of Patients Suspected of Infective Endocarditis: The Prospective Multicenter TEPvENDO Study. Clinical Infectious Diseases, 2021, 73, 393-403.	5.8	41
161	Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After MitraClip Implantation. JACC: Cardiovascular Imaging, 2021, 14, 742-752.	5.3	41
162	Reinterventions after percutaneous mitral commissurotomy during long-term follow-up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. European Heart Journal, 2013, 34, 1923-1930.	2.2	40

#	Article	IF	CITATIONS
163	Impact of Chronic Obstructive Pulmonary Disease on Valve Academic Research Consortium–Defined Outcomes After Transcatheter Aortic Valve Implantation (from the FRANCE 2 Registry). American Journal of Cardiology, 2014, 113, 1543-1549.	1.6	40
164	2015 ESC Guidelines on the management of infective endocarditis: a big step forward for an old disease. Heart, 2016, 102, 992-994.	2.9	40
165	Infective endocarditis: innovations in the management of an old disease. Nature Reviews Cardiology, 2019, 16, 623-635.	13.7	40
166	Trends in aortic valve replacement for aortic stenosis: a French nationwide study. European Heart Journal, 2022, 43, 666-679.	2.2	40
167	Percutaneous mitral commissurotomy for restenosis after surgical commissurotomy. Journal of the American College of Cardiology, 2000, 35, 1295-1302.	2.8	39
168	Contemporary criteria for the selection of patients for percutaneous balloon mitral valvuloplasty. British Heart Journal, 2002, 87, 401-404.	2.1	39
169	Echocardiographic Evaluation of the Mitral Valve Area Before and After Percutaneous Mitral Commissurotomy: The Pressure Half-time Method Revisited. Journal of the American Society of Echocardiography, 2005, 18, 1409-1414.	2.8	39
170	Relationship Between Valve Calcification and Long-Term Results of Percutaneous Mitral Commissurotomy for Rheumatic Mitral Stenosis. Circulation: Cardiovascular Interventions, 2014, 7, 381-389.	3.9	39
171	Influence of percutaneous mitral commissurotomy on left atrial spontaneous contrast of mitral stenosis. American Journal of Cardiology, 1993, 71, 842-847.	1.6	38
172	Management of atrial fibrillation in patients with rheumatic mitral stenosis. Heart, 2018, 104, 1062-1068.	2.9	36
173	3541 Current management of asymptomatic patients with severe aortic regurgitation. European Heart Journal, 2003, 24, 689.	2.2	36
174	Late results of percutaneous mitral commissurotomy for calcific mitral stenosis. American Journal of Cardiology, 2000, 85, 1308-1314.	1.6	35
175	Progression of aortic valve stenosis is associated with bone remodelling and secondary hyperparathyroidism in elderly patientsâ€"the COFRASA study. European Heart Journal, 2013, 34, 1915-1922.	2.2	35
176	Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA–GENERAC study. Heart, 2013, 99, 461-467.	2.9	35
177	Timing of intervention in asymptomatic patients with valvular heart disease. European Heart Journal, 2020, 41, 4349-4356.	2.2	35
178	Sequential assessment of mitral valve area during diastole using colour M-mode flow convergence analysis: new insights into mitral stenosis physiology. European Heart Journal, 2003, 24, 1244-1253.	2.2	34
179	Homograft replacement of the mitral valve: Eight-year results. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 529-534.	0.8	34
180	Impact of Degree of Commissural Opening After Percutaneous Mitral Commissurotomy on Long-Term Outcome. JACC: Cardiovascular Imaging, 2009, 2, 1-7.	5. 3	34

#	Article	IF	Citations
181	Early and mid-term outcomes in patients undergoing transcatheter aortic valve implantation after previous coronary artery bypass grafting. European Journal of Cardio-thoracic Surgery, 2012, 41, 499-504.	1.4	34
182	Transfemoral implantation of an Edwards SAPIEN valve in a tricuspid bioprosthesis without fluoroscopic landmarks. EuroIntervention, 2012, 7, 1336-1339.	3.2	34
183	Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis. Heart, 2010, 96, 696-700.	2.9	33
184	Tricuspid valve and percutaneous approach: No longer the forgotten valve!. Archives of Cardiovascular Diseases, 2016, 109, 55-66.	1.6	33
185	Is the EuroSCORE II reliable to estimate operative mortality among octogenarians?. PLoS ONE, 2017, 12, e0187056.	2.5	33
186	Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial. American Heart Journal, 2018, 200, 67-74.	2.7	33
187	Usefulness of Late Iodine Enhancement on Spectral CT in Acute Myocarditis. JACC: Cardiovascular Imaging, 2017, 10, 826-827.	5.3	32
188	Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over. EuroIntervention, 2016, 12, 883-889.	3.2	32
189	Valvular heart diseases in elderly people. Lancet, The, 2006, 368, 969-971.	13.7	31
190	Transseptal Implantation of a Transcatheter Heart Valve in a Mitral Annuloplasty Ring to Treat Mitral Repair Failure. Circulation: Cardiovascular Interventions, 2011, 4, 396-398.	3.9	31
191	GuÃa de práctica clÃnica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	1.2	31
192	TAVR Patients Requiring Anticoagulation. JACC: Cardiovascular Interventions, 2021, 14, 1704-1713.	2.9	31
193	Silent T2* cerebral microbleeds. Neurology, 2007, 68, 2043-2043.	1.1	30
194	Bail-Out Alcohol Septal Ablation for LeftÂVentricular Outflow Tract ObstructionÂAfter Transcatheter MitralÂValve Replacement. JACC: Cardiovascular Interventions, 2016, 9, e73-e76.	2.9	30
195	Transcatheter Aortic Valve Replacement to Treat Pure Aortic Regurgitation on Noncalcified Native Valves. Journal of the American College of Cardiology, 2016, 68, 1705-1706.	2.8	30
196	Factors associated with 12Âweek case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study. Clinical Microbiology and Infection, 2016, 22, 948.e1-948.e7.	6.0	30
197	Oral Streptococcal Endocarditis, Oral Hygiene Habits, and Recent Dental Procedures: A Case-Control Study. Clinical Infectious Diseases, 2017, 64, 1678-1685.	5.8	30
198	Impact of low preprocedural transvalvular gradient on cardiovascular mortality following TAVI: an analysis from the FRANCE 2 registry. EuroIntervention, 2014, 10, 842-849.	3.2	29

#	Article	IF	CITATIONS
199	Contemporary Management of Severe Symptomatic Aortic Stenosis. Journal of the American College of Cardiology, 2021, 78, 2131-2143.	2.8	29
200	Usefulness of the right parasternal view and non-imaging continuous-wave Doppler transducer for the evaluation of the severity of aortic stenosis in the modern area. European Journal of Echocardiography, 2009, 10, 420-424.	2.3	28
201	Dismal Outcomes and High Societal Burden of Mitral Valve Regurgitation in France in the Recent Era: A Nationwide Perspective. Journal of the American Heart Association, 2020, 9, e016086.	3.7	28
202	Long-term results of mitral valve repair for nonischaemic mitral regurgitation. European Heart Journal, 1991, 12, 39-43.	2.2	27
203	Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries. Human Gene Therapy, 2000, 11, 1329-1339.	2.7	27
204	First Reported Human Case of Native Mitral Infective Endocarditis Caused by Streptococcus canis. Canadian Journal of Cardiology, 2014, 30, 1462.e1-1462.e2.	1.7	27
205	Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room. JACC: Cardiovascular Interventions, 2018, 11, 2195-2203.	2.9	27
206	Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. British Heart Journal, 2002, 88, 20-24.	2.1	26
207	Transfemoral Tricuspid Valve-in-Ring Implantation Using the Edwards Sapien XT Valve. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	26
208	Influence of Sex onÂMortality and Perioperative Outcomes inÂPatients Undergoing TAVR. Journal of the American College of Cardiology, 2015, 65, 755-757.	2.8	26
209	Changing demographics of valvular heart disease and impact on surgical and transcatheter valve therapies. International Journal of Cardiovascular Imaging, 2011, 27, 1115-1122.	1.5	25
210	Cardiac Arrhythmias during the Combined Use of Intravenous Aminophylline and Terbutaline in Status Asthmaticus. Chest, 1988, 94, 496-502.	0.8	24
211	Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT. European Heart Journal, 2003, 24, 613-622.	2.2	24
212	Usefulness of Left Atrial Volume Versus Diameter to Assess Thromboembolic Risk in Mitral Stenosis. American Journal of Cardiology, 2010, 106, 1152-1156.	1.6	24
213	Detection of 18Fluoride Sodium Accumulation by Positron Emission Tomography in Calcified Stenotic Aortic Valves. American Journal of Cardiology, 2012, 109, 1194-1196.	1.6	24
214	Management of Cardiovascular Diseases During Pregnancy. Current Problems in Cardiology, 2014, 39, 85-151.	2.4	24
215	Position paper for the evaluation and management of oral status in patients with valvular disease: Groupe de Travail Valvulopathies de la SociÁ©té Française de Cardiologie, Société Française de Chirurgie Orale, Société Française de Parodontologie et d'Implantologie Orale, Société Française d'Endodontie et Société de Pathologie Infectieuse de Langue Française. Archives of Cardiovascular	1.6	24
216	Diseases, 2017, 110, 462-494. What are the differences in presentation of candidates for percutaneous mitral commissurotomy across the world and do they influence the results of the procedure?. Archives of Cardiovascular Diseases, 2008, 101, 611-617.	1.6	23

#	Article	IF	Citations
217	Percutaneous mitral commissurotomy in the elderly. European Heart Journal, 1995, 16, 1092-1099.	2.2	22
218	Radiotherapy-Induced Mitral Stenosis: A Three-Dimensional Perspective. Journal of the American Society of Echocardiography, 2010, 23, 108.e1-108.e2.	2.8	22
219	Comparison of Outcome of Transcatheter Aortic Valve Implantation With Versus Without Previous Coronary Artery Bypass Grafting (from the FRANCE 2 Registry). American Journal of Cardiology, 2015, 116, 420-425.	1.6	22
220	Valve Thrombosis After Transcatheter Mitral ValveÂReplacement. Journal of the American College of Cardiology, 2016, 68, 1814-1815.	2.8	22
221	Congenital diverticulum of the right ventricle: Report of two cases associated with other congenital heart defects. American Heart Journal, 1989, 117, 957-959.	2.7	21
222	Evaluation of mitral stenosis in 2008. Archives of Cardiovascular Diseases, 2008, 101, 653-663.	1.6	21
223	Exercise testing and exercise stress echocardiography in asymptomatic aortic valve stenosis. Heart, 2009, 95, 877-884.	2.9	21
224	Comparison of Semiquantitative and Quantitative Assessment of Severity of Aortic Regurgitation: Clinical Implications. Journal of the American Society of Echocardiography, 2011, 24, 1246-1252.	2.8	21
225	Feasibility of percutaneous mitral commissurotomy in patients with commissural mitral valve calcification. European Heart Journal, 2014, 35, 1617-1623.	2.2	21
226	Carotid versus femoral access for transcatheter aortic valve implantation: a propensity score inverse probability weighting study. European Journal of Cardio-thoracic Surgery, 2019, 56, 1140-1146.	1.4	21
227	Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. European Heart Journal, 2005, 26, 1831-1837.	2.2	20
228	Transvenous Mitral Valve Replacement After Failure of Surgical Ring Annuloplasty. Journal of the American College of Cardiology, 2012, 60, 1205-1206.	2.8	20
229	Successful linkage of French large-scale national registry populations to national reimbursement data: Improved data completeness and minimized loss to follow-up. Archives of Cardiovascular Diseases, 2020, 113, 534-541.	1.6	20
230	Characteristics and Outcome of COAPT-Eligible Patients in the MITRA-FR Trial. Circulation, 2020, 142, 2482-2484.	1.6	20
231	Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin. Heart, 2009, 95, 1694-1700.	2.9	19
232	The â€~wait for symptoms' strategy in asymptomatic severe aortic stenosis. Heart, 2020, 106, 1792-1797.	2.9	19
233	Presentation and outcomes of mitral valve surgery in France in the recent era: a nationwide perspective. Open Heart, 2020, 7, e001339.	2.3	19
234	Management and Outcome of Patients Admitted With Tricuspid Regurgitation in France. Canadian Journal of Cardiology, 2021, 37, 1078-1085.	1.7	19

#	Article	IF	Citations
235	Evaluation of mitral valve area by the proximal isovelocity surface area method in mitral stenosis: Could it be simplified?. European Journal of Echocardiography, 2007, 8, 116-121.	2.3	18
236	Transcatheter aortic valve implantation: Our vision of the future. Archives of Cardiovascular Diseases, 2012, 105, 181-186.	1.6	18
237	Long-term efficacy of percutaneous mitral commissurotomy for restenosis after previous mitral commissurotomy. Heart, 2013, 99, 1336-1341.	2.9	18
238	Early and late outcomes after trans-catheter aortic valve implantation in patients with previous chest radiation. Heart, 2016, 102, 1044-1051.	2.9	18
239	Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCEâ€2 registry. Clinical Cardiology, 2017, 40, 1316-1322.	1.8	18
240	Analysis of length of stay after transfemoral transcatheter aortic valve replacement: results from the FRANCE TAVI registry. Clinical Research in Cardiology, 2021, 110, 40-49.	3.3	18
241	The 2011-2012 pilot European Society of Cardiology Sentinel Registry of Transcatheter Aortic Valve Implantation: 12-month clinical outcomes. EuroIntervention, 2016, 12, 79-87.	3.2	18
242	Immediate and mid-term results of transfemoral aortic valve implantation using either the Edwards Sapienâ,,¢ transcatheter heart valve or the Medtronic CoreValve® System in high-risk patients with aortic stenosis. Archives of Cardiovascular Diseases, 2010, 103, 236-245.	1.6	17
243	Transoesophageal echocardiography in the assessment of percutaneous mitral commissurotomy. European Heart Journal, 1991, 12, 61-65.	2.2	16
244	Management of asymptomatic patients with severe non-ischaemic mitral regurgitation. Are practices consistent with guidelines?. European Journal of Cardio-thoracic Surgery, 2008, 34, 937-942.	1.4	16
245	Prognostic value of new onset atrial fibrillation after transcatheter aortic valve implantation: A FRANCE 2 registry substudy. International Journal of Cardiology, 2016, 210, 72-79.	1.7	16
246	"Rescue―abciximab for complicated percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1998, 82, 800-803.	1.6	15
247	Actual management of patients with asymptomatic aortic valve disease: How practice fits with guidelines. American Heart Journal, 2007, 153, 696-703.	2.7	15
248	The MITRA-HR study: design and rationale of a randomised study of MitraClip transcatheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery. EuroIntervention, 2019, 15, e329-e335.	3.2	15
249	Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. European Heart Journal, 2022, 43, 2756-2766.	2.2	15
250	The long-term outcome of balloon valvuloplasty for mitral stenosis. Current Cardiology Reports, 2002, 4, 118-124.	2.9	14
251	Real-time 3D transoesophageal measurement of the mitral valve area in patients with mitral stenosis. European Journal of Echocardiography, 2011, 12, 750-755.	2.3	14
252	Specifics of technique in percutaneous mitral commissurotomy in a case of dextrocardia and situs inversus with mitral stenosis., 1996, 39, 85-88.		13

#	Article	IF	Citations
253	Transarterial Medtronic CoreValve System Implantation for Degenerated Surgically Implanted Aortic Prostheses. Circulation: Cardiovascular Interventions, 2011, 4, 488-494.	3.9	13
254	Towards improved risk scores: the quest for the grail continues. European Heart Journal, 2013, 34, 10-12.	2.2	13
255	Cardiac Imaging of Infective Endocarditis, Echo and Beyond. Current Infectious Disease Reports, 2017, 19, 8.	3.0	13
256	Standards defining a †Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. European Journal of Cardiothoracic Surgery, 2017, 52, 418-424.	1.4	13
257	Role of Calcium Channel Blockers in Reducing Acute Ischaemia and Preventing Restenosis in PTCA. Drugs, 1996, 52, 9-16.	10.9	12
258	GuÃa de práctica clÃnica de la ESC para el tratamiento de las enfermedades cardiovasculares durante el embarazo. Revista Espanola De Cardiologia, 2012, 65, 171.e1-171.e44.	1.2	12
259	Temporal Trends on Percutaneous Mitral Commissurotomy: 30ÂYears of Experience. Journal of the American Heart Association, 2019, 8, e012031.	3.7	12
260	Using surgical risk scores in nonsurgically treated infective endocarditis patients. Hellenic Journal of Cardiology, 2020, 61, 246-252.	1.0	12
261	Diagnostic performance of White Blood Cell SPECT imaging against intra-operative findings in patients with a suspicion of prosthetic valve endocarditis. Journal of Nuclear Cardiology, 2022, 29, 528-534.	2.1	12
262	A Step Forward in the Evaluation of Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2010, 55, 1091-1092.	2.8	11
263	Management of asymptomatic aortic stenosis. Heart, 2011, 97, 253-259.	2.9	11
264	Eclipsed mitral regurgitation: an unusual cause of acute heart failure. European Heart Journal Cardiovascular Imaging, 2017, 18, 1163-1169.	1.2	11
265	Thromboembolic events early after mitral valve repair: Incidence and predictive factors. International Journal of Cardiology, 2008, 126, 45-52.	1.7	10
266	Transient severe reversible functional mitral regurgitation: a three-dimensional transoesophageal perspective. European Heart Journal Cardiovascular Imaging, 2010, 11, E3-E3.	1.2	10
267	Calcifications in Benfluorex-Induced Valve Heart Disease: A Misknown Association. Cardiology, 2015, 130, 87-90.	1.4	10
268	Comparison of Outcomes After One-Versus-Two Transcatheter Aortic Valve Implantation During a Same Procedure (from the FRANCE2 Registry). American Journal of Cardiology, 2015, 115, 1273-1280.	1.6	10
269	Current recommendations for anticoagulant therapy in patients with valvular heart disease and atrial fibrillation: the ACC/AHA and ESC/EACTS Guidelines in Harmony…but not Lockstep!. Heart, 2018, 104, 968-970.	2.9	10
270	Valve-in-Valve and Valve-in-Ring Transcatheter Mitral Valve Implantation in Young Women Contemplating Pregnancy. Circulation: Cardiovascular Interventions, 2020, 13, e009579.	3.9	10

#	Article	IF	Citations
271	Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry. Infection, 2022, 50, 1191-1202.	4.7	10
272	Echocardiographic Criteria in Selection of Patients for Percutaneous Mitral Commissurotomy. Echocardiography, 1999, 16, 711-721.	0.9	9
273	Cardiac cause of hypoxaemia in a kyphoscoliotic patient. European Respiratory Journal, 1999, 14, 1433-1434.	6.7	9
274	Mitral stenosis still a concern in heart valve diseases. Archives of Cardiovascular Diseases, 2008, 101, 597-599.	1.6	9
275	Ethnic disparities in the incidence of infective endocarditis in the Pacific. International Journal of Cardiology, 2015, 186, 43-44.	1.7	9
276	The impact of the development of transcatheter aortic valve implantation on the management of severe aortic stenosis in high-risk patients: treatment strategies and outcome. European Journal of Cardio-thoracic Surgery, 2017, 51, 80-88.	1.4	9
277	Impact of referral bias on prognostic studies outcomes: insights from a population-based cohort study on infective endocarditis. Annals of Epidemiology, 2021, 54, 29-37.	1.9	9
278	Cancer and Infective Endocarditis: Characteristics and Prognostic Impact. Frontiers in Cardiovascular Medicine, 2021, 8, 766996.	2.4	9
279	Evolution of TAVI patients and techniques over the past decade: The French TAVI registries. Archives of Cardiovascular Diseases, 2022, 115, 206-213.	1.6	9
280	Fetal and Obstetrical Impact of Percutaneous Balloon Mitral Commissurotomy during Pregnancy. Fetal Diagnosis and Therapy, 1994, 9, 218-225.	1.4	8
281	A Comparison of Bilateral with Single Internal Mammary Artery Grafts on Postoperative Mediastinal Drainage and Transfusion Requirement. Anesthesia and Analgesia, 2006, 103, 1380-1385.	2.2	8
282	Mitral Leaflet Separation Index: A New Method for the Evaluation of the Severity of Mitral Stenosis? Usefulness Before and After Percutaneous Mitral Commissurotomy. Journal of the American Society of Echocardiography, 2007, 20, 1119-1124.	2.8	8
283	Clinical outcomes and direct costs after transcatheter aortic valve implantation in French centres: a longitudinal study of 1332 patients using a national database. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 883-888.	1.1	8
284	Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery. European Journal of Cardio-thoracic Surgery, 2016, 50, 1132-1138.	1.4	8
285	Corrigendum to: 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2018, 39, 1980-1980.	2.2	8
286	Risk Stratification in Patients With Aortic Stenosis. JACC: Cardiovascular Interventions, 2019, 12, 2169-2172.	2.9	8
287	Predictors and clinical impact of thrombosis after transcatheter mitral valve implantation using balloon-expandable bioprostheses. EuroIntervention, 2021, 16, 1455-1462.	3.2	8
288	An interdisciplinary debate initiated by the European Society of Cardiology Working Group on Valvular Heart Disease. EuroIntervention, 2012, 7, 1257-1274.	3.2	8

#	Article	IF	Citations
289	Percutaneous valve procedures: Present and future. International Journal of Cardiovascular Interventions, 2005, 7, 14-20.	0.5	7
290	GuÃa de práctica clÃnica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugÃa no cardiaca. Revista Espanola De Cardiologia, 2009, 62, 1467.e1-1467.e56.	1.2	7
291	Aortic root dilatation in young patients with cryptogenic stroke and patent foramen ovale. Archives of Cardiovascular Diseases, 2012, 105, 13-17.	1.6	7
292	Echocardiographic measurement of left atrial volume: Does the method matter?. Archives of Cardiovascular Diseases, 2015, 108, 643-649.	1.6	7
293	Infective endocarditis in the Pacific: clinical characteristics, treatment and long-term outcomes. Open Heart, 2015, 2, e000183.	2.3	7
294	Usefulness of Subepicardial Hyperemia on Contrast-Enhanced First-Pass Magnetic Resonance Perfusion Imaging for Diagnosis of Acute Myocarditis. American Journal of Cardiology, 2016, 118, 440-445.	1.6	7
295	The TVT Registry. Journal of the American College of Cardiology, 2017, 69, 1231-1233.	2.8	7
296	Extracardiac Imaging of Infective Endocarditis. Current Infectious Disease Reports, 2017, 19, 24.	3.0	7
297	The Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis () Tj ETQq1	1 <u>0.</u> 78431	4 _, rgBT /O <mark>ve</mark>
298	Impact of moderate to severe mitral stenosis in patients undergoing transcatheter aortic valve replacement. International Journal of Cardiology, 2019, 286, 36-42.	1.7	7
299	Antibiotic prophylaxis of infective endocarditis in patients with predisposing cardiac conditions: French cardiologists' implementation of current guidelines. International Journal of Cardiology, 2020, 299, 222-227.	1.7	7
300	Silent coronary artery disease in asymptomatic patients with severe aortic stenosis and normal exercise testing. Coronary Artery Disease, 2020, 31, 166-173.	0.7	7
301	Evaluation of length of stay after transfemoral transcatheter aortic valve implantation with SAPIEN 3 prosthesis: A French multicentre prospective observational trial. Archives of Cardiovascular Diseases, 2020, 113, 391-400.	1.6	7
302	Infective endocarditis in French Polynesia: Epidemiology, treatments and outcomes. Archives of Cardiovascular Diseases, 2020, 113, 252-262.	1.6	7
303	High Post-Procedural Transvalvular Gradient or Delayed Mean Gradient Increase after Transcatheter Aortic Valve Implantation: Incidence, Prognosis and Associated Variables. The FRANCE-2 Registry. Journal of Clinical Medicine, 2021, 10, 3221.	2.4	7
304	Characteristics, management, and outcomes of patients with leftâ€sided infective endocarditis complicated by heart failure: a substudy of the <scp>ESCâ€EORP EUROâ€ENDO</scp> (European infective) Tj ETC	Отд0 00 rg	şΒπ /Overloc
305	Degenerative aortic regurgitation. European Heart Journal, 1991, , .	2.2	6
306	Transcatheter Aortic ValveÂlmplantation. Journal of the American College of Cardiology, 2013, 62, 1013-1014.	2.8	6

#	Article	IF	CITATIONS
307	Severe secondary mitral regurgitation and left ventricular dysfunction: a †deadly combination†against which the fight is not over!: Figure 1. European Heart Journal, 2015, 36, 2742-2744.	2.2	6
308	Diagnosis of acute myocarditis with dual source cardiac tomography. International Journal of Cardiology, 2015, 179, 256-257.	1.7	6
309	Role of cardiovascular biomarkers for the assessment of mitral stenosis and its complications. European Journal of Internal Medicine, 2016, 34, 58-62.	2.2	6
310	Causes and temporal trends in procedural deaths after transcatheter aortic valve implantation. Archives of Cardiovascular Diseases, 2017, 110, 607-615.	1.6	6
311	Neurologic Complications of Infective Endocarditis. Critical Care Medicine, 2019, 47, e685-e692.	0.9	6
312	'Edge to edge' percutaneous mitral valve repair in mitral regurgitation: it can be done but should it be done?. European Heart Journal, 2010, 31, 1301-1304.	2.2	5
313	latrogenic aortic valve perforation assessed using three-dimensional transoesophageal echocardiography. Archives of Cardiovascular Diseases, 2011, 104, 486-487.	1.6	5
314	Determinants of regurgitant volume in mitral regurgitation: contrasting effect of similar effective regurgitant orifice area in functional and organic mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2012, 13, 324-329.	1,2	5
315	Lessons from the RE-ALIGN trial. Archives of Cardiovascular Diseases, 2014, 107, 277-279.	1.6	5
316	Impact of previous acute pulmonary oedema after transcatheter aortic valve implantation: Insight from French Aortic National CoreValve and Edwards 2 [FRANCE 2]registry. International Journal of Cardiology, 2015, 183, 98-104.	1.7	5
317	Infective endocarditis and antibiotic prophylaxis. Lancet, The, 2015, 386, 529-530.	13.7	5
318	Retrospective study of anaesthetic management of pregnancy patients with mechanical heart valve prosthesis and anticoagulants. Anaesthesia, Critical Care & Dain Medicine, 2018, 37, 225-231.	1.4	5
319	18F-FDG PET/CT in Infective Endocarditis. Journal of the American College of Cardiology, 2019, 74, 1041-1043.	2.8	5
320	Atrial Fibrillation and Aortic Stenosis. JACC: Cardiovascular Interventions, 2020, 13, 2134-2136.	2.9	5
321	Impact of Mitral Annular Calcium and Mitral Stenosis on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 155, 103-112.	1.6	5
322	Percutaneous mitral balloon commissurotomy: a useful and necessary treatment for the western population. European Heart Journal, 2000, 21, 1651-1652.	2.2	4
323	Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2011, 58, 2139-2140.	2.8	4
324	Treatment of mitral regurgitation: From sternotomy to percutaneous approach – A paradigm shift?. Archives of Cardiovascular Diseases, 2012, 105, 401-403.	1.6	4

#	Article	IF	CITATIONS
325	TCT-92 Does mitral regurgitation impact the outcome of TAVI procedures? Insights from the FRANCE2 Registry. Journal of the American College of Cardiology, 2012, 60, B29.	2.8	4
326	New ESC guidelines: aortic disease: TableÂ1. Heart, 2015, 101, 421-423.	2.9	4
327	Response: Asymptomatic severe aortic stenosis: Cardiopulmonary exercise testing in "the world of AVATAR― American Heart Journal, 2016, 178, e3-e4.	2.7	4
328	Baseline characteristics and outcomes after transcatheter aortic-valve implantation in patients with or without previous balloon aortic valvuloplasty: Insights from the FRANCE 2 registry. Archives of Cardiovascular Diseases, 2017, 110, 534-542.	1.6	4
329	Coronary obstruction: a rare but devastating complication during transcatheter aortic valve-in-valve implantation. European Heart Journal, 2018, 39, 696-698.	2.2	4
330	Outcomes of Transcatheter Aortic Valve Implantation in Patients Receiving Chronic Systemic Corticosteroid Treatment. American Journal of Cardiology, 2020, 130, 108-114.	1.6	4
331	Prognostic Value of Peak Exercise Systolic Pulmonary Arterial Pressure in Asymptomatic Primary Mitral Valve Regurgitation. Journal of the American Society of Echocardiography, 2021, 34, 932-940.	2.8	4
332	Current treatment of symptomatic aortic stenosis in elderly patients: Do risk scores really matter after 80 years of age?. Archives of Cardiovascular Diseases, 2021, 114, 624-633.	1.6	4
333	A nationwide contemporary epidemiological portrait of valvular heart diseases. Heart, 2017, 103, 1660-1662.	2.9	4
334	Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends. Current Pharmaceutical Design, 2017, 23, 4687-4695.	1.9	4
335	Les cardiopathies acquises de l'enfant dans les pays en voie de développement. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 315-326.	0.0	4
336	New insights into transcatheter edge-to-edge repair: filling a gap for undertreatment of primary mitral regurgitation in the elderly?. European Heart Journal, 2022, 43, 1636-1638.	2.2	4
337	Pregnancy-related cardiac complications: A consequence of the burden of rheumatic heart disease in sub-Saharan Africa. Archives of Cardiovascular Diseases, 2011, 104, 367-369.	1.6	3
338	Measurement of the Aortic Annulus Diameter Using Transesophageal Echocardiography and Multislice Computed Tomography—Are They Truly Comparable?. Canadian Journal of Cardiology, 2014, 30, 1073-1079.	1.7	3
339	Response to Letters Regarding Article, "Infective Endocarditis After Transcatheter Aortic Valve Implantation: Results From a Large Multicenter Registry― Circulation, 2015, 132, e372-4.	1.6	3
340	Mitral regurgitation. Herz, 2016, 41, 3-9.	1.1	3
341	Response by Mathieu et al to Letter Regarding Article, "Characterization of 18 F-Fluorodeoxyglucose Uptake Pattern in Noninfected Prosthetic Heart Valves― Circulation: Cardiovascular Imaging, 2017, 10,	2.6	3
342	Performing optimal transcatheter aortic valve implantation: The need for tailored use of transcatheter valves. Archives of Cardiovascular Diseases, 2019, 112, 512-522.	1.6	3

#	Article	IF	Citations
343	Cardiovascular research in France: Evolution of scientific activities and production over the last decade. Archives of Cardiovascular Diseases, 2019, 112, 241-252.	1.6	3
344	Transcatheter tricuspid valveâ€inâ€valve replacement: Making it simpler. Catheterization and Cardiovascular Interventions, 2020, 95, 65-67.	1.7	3
345	The disproportionate success of the disproportionate concept. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e7-e8.	0.8	3
346	Are We Right to Believe in the Value of Transcatheter Treatment of Secondary Tricuspid Regurgitation?. Journal of the American College of Cardiology, 2021, 77, 240-242.	2.8	3
347	Rheumatic Mitral Valve Disease. , 2009, , 221-242.		3
348	The year in cardiovascular medicine 2021: valvular heart disease. European Heart Journal, 2022, 43, 633-640.	2.2	3
349	Global threat of rheumatic heart disease: do not forget children!. Heart, 2022, 108, 582-583.	2.9	3
350	The valve patient and pregnancy. Expert Review of Cardiovascular Therapy, 2008, 6, 1249-1258.	1.5	2
351	Nitrous oxide inhalation for transoesophageal echocardiography: an alternative to benzodiazepine sedation?. European Journal of Echocardiography, 2008, 9, 621-624.	2.3	2
352	Understanding Risk Assessment in Cardiac Surgery Patients. Seminars in Thoracic and Cardiovascular Surgery, 2010, 22, 285-290.	0.6	2
353	Atrial Fibrillation Following Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 59, 189-190.	2.8	2
354	GuÃade práctica clÃnica sobre el tratamiento de las valvulopatÃas (versión 2012). Revista Espanola De Cardiologia, 2013, 66, 131.e1-131.e42.	1.2	2
355	Implications of the new AHA/ACC valvular disease guidelines. Nature Reviews Cardiology, 2014, 11, 317-318.	13.7	2
356	Response to Letter Regarding Article, "Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement Procedures: Analysis of Predictors and Impact on Long-Term Mortality: Insights From the FRANCE2 Registry― Circulation, 2015, 131, e16-7.	1.6	2
357	Predicting the outcome of degenerative mitral regurgitation: a step forward but still a long way to go!. European Heart Journal, 2018, 39, 1292-1294.	2.2	2
358	Addressing the Treatment Dilemma in Asymptomatic Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 1896-1897.	5. 3	2
359	Towards an increased awareness on infective endocarditis in patients with bloodstream infections: a role for multivariate scores?. European Heart Journal, 2019, 40, 3245-3247.	2.2	2
360	A New Match Between Surgery and Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 73, 1656-1658.	2.8	2

#	Article	IF	Citations
361	NYHA Functional Class in Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2329-2330.	2.9	2
362	Valve-in-valve vs. repeat surgical aortic valve replacement: a new match but the game is not over!. European Heart Journal, 2020, 41, 2756-2758.	2.2	2
363	Adverse cardiovascular disease outcomes in patients with aortic sclerosis and mitral annular calcification even when valve function is normal. Heart, 2021, 107, 1280-1281.	2.9	2
364	Community burden of aortic valve disease. Heart, 2021, 107, 1446-1447.	2.9	2
365	Causes and predictors of mortality after transcatheter mitral valve implantation in patients with severe mitral annulus calcification. Catheterization and Cardiovascular Interventions, 2021, 98, 981-989.	1.7	2
366	Unmet clinical needs in transcatheter mitral valve interventions in 2014. EuroIntervention, 2014, 10, U101-U105.	3.2	2
367	Transcatheter valves and interventional cardiology. EuroIntervention, 2011, 6, 673-677.	3.2	2
368	Poor oral health and hygiene habits in patients with infective endocarditis and previously identified predisposing cardiac condition: A prospective cohort study. Journal of Infection, 2022, 84, e58-e61.	3.3	2
369	Cardioprotective Effect of Intracoronary Diltiazem in Myocardial Ischaemia Induced by Percutaneous Transluminal Coronary Angioplasty. Clinical Drug Investigation, 1996, 11, 261-269.	2.2	1
370	Corrigendum to: 'Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)' [Eur Heart J 2009;30:2769-2812].	2.2	1
371	European Heart Journal, 2010, 31, 379-379. Percutaneous treatment of mitral regurgitation: From feasibility to clinical application?. Archives of Cardiovascular Diseases, 2011, 104, 1-3.	1.6	1
372	Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic-valve implantation: study from the FRANCE 2 registry. European Heart Journal, 2013, 34, 2582-2582.	2.2	1
373	Considerations on the poor discriminatory power of the FRANCE-2 risk score: Authors' reply. Heart, 2015, 101, 1170-1170.	2.9	1
374	Quality of life after transcatheter aortic valve implantation: the need for more a complete appraisal. European Heart Journal Quality of Care & Dinical Outcomes, 2016, 2, 147-148.	4.0	1
375	The year in cardiology 2015: valvular heart disease. European Heart Journal, 2016, 37, 442-448.	2.2	1
376	Valve weight in aortic stenosis: back to the basics: TableÂ1. European Heart Journal, 2016, 37, 700-702.	2.2	1
377	Is Transesophageal Echocardiography Needed before Hospital Discharge in Patients after Bentall Surgery?. Journal of the American Society of Echocardiography, 2017, 30, 52-58.	2.8	1
378	Postoperative Cardiac Troponin I Thresholds Associated With 1-Year Cardiac Mortality After Adult Cardiac Surgery: An Attempt to Link Risk Stratification With Management Stratification in an Observational Study. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 3320-3330.	1.3	1

#	Article	IF	CITATIONS
379	Transcatheter Mitral Valve Repair in Secondary MR. Journal of the American College of Cardiology, 2019, 73, 2133-2134.	2.8	1
380	Data on prognostic factors associated with 3-month and 1-year mortality from infective endocarditis. Data in Brief, 2020, 33, 106478.	1.0	1
381	Management of myocardial infarction: Pay more attention to comorbidities. International Journal of Cardiology, 2020, 308, 13-14.	1.7	1
382	Endocarditis caused by Thalassospira sp IDCases, 2021, 24, e01109.	0.9	1
383	Atrioventricular valve regurgitation: still a long road ahead. Heart, 2021, 107, 947-948.	2.9	1
384	Major adverse cardiovascular events and anaesthetic management in pregnant women with cardiac disease: a retrospective, single-centre study. British Journal of Anaesthesia, 2021, 127, e8-e10.	3.4	1
385	Rheumatic Heart Disease. , 0, , 79-95.		1
386	Prevalence and Definition of Secondary Mitral Regurgitation. , 2015, , 1-6.		1
387	Echocardiography in the Patient Undergoing Catheter Balloon Mitral Valvuloplasty: Patient Selection, Hemodynamic Results, Complications, and Long-Term Outcome., 2007,, 481-501.		1
388	Long-Term Results After Percutaneous Balloon Mitral Commissurotomy. Journal of Interventional Cardiology, 2000, 13, 281-285.	1.2	0
389	Rheumatic Heart Disease and Percutaneous Mitral Commissurotomy Across the World. Heart Lung and Circulation, 2009, 18, 372-373.	0.4	0
390	083 CEREBRAL MICROBLEEDS: A NEW DIAGNOSTIC CLUE IN INFECTIVE ENDOCARDITIS. International Journal of Antimicrobial Agents, 2009, 33, S31-S32.	2.5	0
391	GuÃa de práctica clÃnica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugÃa no cardiaca. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1467.e1-1467.e56.	0.6	0
392	When chest pain reveals a Fabry disease. Presse Medicale, 2011, 40, 540-544.	1.9	0
393	Heart disease in pregnant women: Recent ESC guidelines. Archives of Cardiovascular Diseases, 2012, 105, 57-59.	1.6	0
394	P81 IMPACT OF VALVE SURGERY IN PATIENTS WITH INFECTIVE ENDOCARDITIS AND NEUROLOGICAL COMPLICATIONS. International Journal of Antimicrobial Agents, 2013, 41, S31.	2.5	0
395	Is the Euroscore II reliable to estimate operative mortality of valvular surgery?. European Heart Journal, 2013, 34, 5954-5954.	2,2	0
396	Transfemoral implantation of percutaneous heart valves following atrioventricular bioprosthesis and ring annuloplasty failure. European Heart Journal, 2013, 34, P2158-P2158.	2,2	0

#	Article	IF	CITATIONS
397	Impact of valve surgery in patients with infective endocarditis and neurological complications. European Heart Journal, 2013, 34, P4775-P4775.	2.2	0
398	Measurement of the aortic annulus diameter using transesophageal echocardiography and multislice computed tomography. Are they interchangeable? European Heart Journal, 2013, 34, P5417-P5417.	2.2	0
399	Feasibility of percutaneous mitral commissurotomy in patients with commissural mitral valve calcifications. European Heart Journal, 2013, 34, 1623-1623.	2.2	0
400	Procedural predictors of Post-TAVR Aortic Regurgitation for Balloon-expendable and Self-expendable devices? Insights from the France 2 registry. European Heart Journal, 2013, 34, 3760-3760.	2.2	0
401	Impact of chronic obstructive pulmonary disease on one year mortality after transcatheter aortic valve implantation. A substudy from the FRANCE 2 nationwide registry. European Heart Journal, 2013, 34, P5395-P5395.	2.2	O
402	What are the predictive performance and limitations of the Euroscore II?. European Heart Journal, 2013, 34, P2175-P2175.	2.2	0
403	Anticoagulation in Pregnancy. , 2014, , 79-105.		0
404	Pregnancy in a Patient With Severe Aortic Stenosis Requiring Unusual Management. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 1632-1635.	1.3	0
405	Antithrombotic therapy after transcatheter aortic valve implantation: TableÂ1. Heart, 2015, 101, 1089-1090.	2.9	0
406	Hemodynamic Complications in Infective Endocarditis. , 2016, , 107-121.		0
407	The TVT Registry: Collaboration Leading to Quality Control. Annals of Thoracic Surgery, 2017, 103, 693-694.	1.3	0
408	The need for a continuing awareness of the quality of anticoagulant therapy in patients with mechanical prostheses. Heart, 2017, 103, 179-180.	2.9	0
409	Non cardiac surgery and aortic stenosis. Sang Thrombose Vaisseaux, 2018, 30, 254-260.	0.1	0
410	Response to: ‴Current recommendations for anticoagulant therapy in patients with valvular heart disease and atrial fibrillation: the ACC/AHA and ESC/EACTS Guidelines in Harmony…but not Lockstep!'. Heart, 2018, 104, 2077.2-2077.	2.9	0
411	Analysis of disparities in length of hospital stay after transfemoral transcatheter aortic valve implantation: Results from the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) Registry. Archives of Cardiovascular Diseases Supplements, 2019, 11, 64.	0.0	0
412	Hospital Resource Use After TAVR. Journal of the American College of Cardiology, 2019, 73, 1147-1148.	2.8	0
413	Transcatheter mitral valve repair for primary and secondary mitral regurgitation: new insights from a nationwide registry. European Journal of Heart Failure, 2021, 23, 1377-1379.	7.1	O
414	P2278 Unexpected findings in anticoagulation management in patients with valvular heart disease after valve surgery. European Heart Journal, 2003, 24, 437.	2.2	0

#	Article	IF	CITATIONS
415	Late results, up to 20 year follow-up, of percutaneous mitral commissurotomy. Sang Thrombose Vaisseaux, 2013, 25, 281-290.	0.1	0
416	Ten-Year Results of Percutaneous Mitral Commissurotomy in a Series of 1024 Patients. Journal of the American College of Cardiology, 1998, 31, 74A-75A.	2.8	0
417	Is it Possible to Perform Valve Repair for Severe Mitral Regurgitation After Percutaneous Mitral Commissurotomy?. Journal of the American College of Cardiology, 1998, 31, 27A.	2.8	0
418	Commissural Prolapse: A Marker of Severity for Mitral Valve Repair. Journal of the American College of Cardiology, 1998, 31, 28A.	2.8	0
419	Cost-Benefit of TAVR: Should Indications Be Expanded?. , 2015, , 385-397.		O
420	Percutaneous mitral valve repair in severe secondary mitral regurgitation: Analysis of index hospitalization and economic evaluation based on the MITRA-FR trial. Archives of Cardiovascular Diseases, 2021, 114, 805-813.	1.6	0
421	One-year outcome after cardiac surgery of patients with cancer: an observational monocentric retrospective study Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	1.3	0
422	Mitral valveâ€inâ€valve and valveâ€inâ€ring procedures: Midterm outcomes in a French nationwide registry. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0
423	The year in cardiovascular medicine 2021: valvular heart disease. Cardiologia Croatica, 2022, 17, 44-58.	0.0	0
424	Antegrade transseptal coronary angiography: An alternative technique in severe vascular disease. Catheterization and Cardiovascular Diagnosis, 1998, 43, 444-446.	0.3	0